Enovis (NYSE:ENOV) Reaches New 52-Week Low on Analyst Downgrade

Enovis Corporation (NYSE:ENOV)’s stock price hit a new 52-week low during mid-day trading on Wednesday after Zacks Research downgraded the stock from a hold rating to a strong sell rating. The company traded as low as $19.14 and last traded at $20.7340, with a volume of 2373298 shares changing hands. The stock had previously closed at $22.02.

Other equities analysts have also issued research reports about the company. Wall Street Zen lowered Enovis from a “buy” rating to a “hold” rating in a research report on Sunday, June 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Evercore reissued an “outperform” rating and set a $36.00 price objective on shares of Enovis in a report on Friday, May 8th. William Blair began coverage on shares of Enovis in a research report on Friday, April 17th. They set an “outperform” rating on the stock. Finally, BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Enovis in a research report on Friday, May 22nd. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $44.50.

Insider Transactions at Enovis

In other news, insider Oliver Engert purchased 1,200 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders bought 4,200 shares of company stock valued at $92,084 over the last 90 days. Company insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Several institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System boosted its stake in Enovis by 1.2% in the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock worth $1,622,000 after purchasing an additional 621 shares in the last quarter. MGO One Seven LLC increased its stake in Enovis by 9.4% during the 4th quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock valued at $202,000 after purchasing an additional 650 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of Enovis by 13.0% in the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the last quarter. Finally, Inscription Capital LLC raised its holdings in shares of Enovis by 9.4% in the fourth quarter. Inscription Capital LLC now owns 11,869 shares of the company’s stock worth $316,000 after buying an additional 1,016 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Stock Up 12.8%

The company’s 50 day moving average price is $23.25 and its 200 day moving average price is $23.87. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -1.14 and a beta of 1.39.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The firm had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, research analysts forecast that Enovis Corporation will post 3.12 earnings per share for the current fiscal year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.